Cargando…

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons

BACKGROUND: Until recently, treatments for older patients with AML ineligible to receive intensive chemotherapies were limited to hypomethylating agents, low-dose cytarabine (LDAC), or clinical trials. In 2018, the FDA approved combination glasdegib (GLAS) plus LDAC based on Phase II results demonst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tremblay, Gabriel, Westley, Tracy, Cappelleri, Joseph C, Arondekar, Bhakti, Chan, Geoffrey, Bell, Timothy J, Briggs, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735653/ https://www.ncbi.nlm.nih.gov/pubmed/31564931 http://dx.doi.org/10.2147/CEOR.S203482

Ejemplares similares

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Cytarabine/glasdegib: COVID-19 infection and CNS haemorrhage: 2 case reports
Publicado: (2021)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
por: Daver, Naval G., et al.
Publicado: (2023)

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy
por: Solem, Caitlyn T., et al.
Publicado: (2020)

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
por: Sekeres, Mikkael A., et al.
Publicado: (2023)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
por: Relias, Valerie, et al.
Publicado: (2020)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
por: Cortes, Jorge E., et al.
Publicado: (2020)

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML
por: Hong, Ming, et al.
Publicado: (2020)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Cortes, Jorge E., et al.
Publicado: (2018)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
por: Li, Jun, et al.
Publicado: (2022)

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
por: Lin, Swan, et al.
Publicado: (2020)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
por: Liu, Jing, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
por: Taenaka, Ryutaro, et al.
Publicado: (2022)

Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine
por: Zhang, Alexander, et al.
Publicado: (2022)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
por: Pawlak, Alicja, et al.
Publicado: (2022)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
por: Heuser, Michael, et al.
Publicado: (2021)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
por: Heuser, Michael, et al.
Publicado: (2021)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_lltnftmsscr391jeablee5avdf